Immunogenicity regulation of genetically engineered vaccine and its potential in tumor treatment

Zhuoran Yang

doi:10.62051/ya8xjh67

Authors

Zhuoran Yang

DOI:

https://doi.org/10.62051/ya8xjh67

Keywords:

Immunogenicity regulation; genetically engineered vaccine; tumor treatment.

Abstract

In this study, the strategy of enhancing immunogenicity of genetically engineered vaccine and its application potential in tumor treatment were discussed. Firstly, the study explained the principle that genetic engineering vaccine designed antigen by gene recombination technology to trigger strong immune response. By adjusting gene combination, improving vaccine delivery system and using adjuvant, the immune stimulation ability and delivery efficiency of vaccine were improved. Especially in tumor therapy, these vaccines stimulate specific immune responses against specific or related tumor antigens. This paper also summarizes the clinical manifestations of mRNA cancer vaccine and individualized cancer vaccine, and discusses the combined application with traditional treatment methods such as chemotherapy, radiotherapy, targeted therapy and immune checkpoint inhibitors, in order to improve the treatment effect and the diversity of patients' treatment options.

Downloads

Download data is not yet available.

References

[1] Suh, K. W., Piantadosi, S., Yazdi, H. A. , Pardoll, D. M. , & Choti, M. A. (2015). Treament of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte‐macrophage colony‐stimulating factor. Journal of Surgical Oncology, 72(4), 218-224.

[2] Ma, S. , Wang, L. , Huang, X. , Wang, X. , Chen, S. , & Shi, W. , et al. (2018). Oral recombinant lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus. Microbial Cell Factories, 17(1), 20.

[3] Du, J., Wang, T., & Xu L.Wang C.Liu Y.Pan C.Chen X.Zhu Z.Luo Y.Yin C. (2023). Clostridium perfringens epsilon prototoxin mutant rpetxy30a/y71a/h106p/y196a as a vaccine candidate against enterotoxemia. Vaccine, 41(32), 4762-4770.

[4] Erdogan, M. A. , Gurbuz, O. , & Bozkurt, F. E. O. (2024). Prenatal exposure to covid-19 mrna vaccine bnt162b2 induces autism-like behaviors in male neonatal rats: insights into wnt and bdnf signaling perturbations. Neurochemical research, 49(4), 1034-1048.

[5] Kevliius, L., Ablauskas, K., & Kazimieras ManeikisDovil JuozapaitUgn RingeleviiūtVilmant VaiteknaitBirut DavainienGuoda DauklaitDominika VasilevskaMindaugas StokusIeva NarkeviiūtVioleta SivickienKstutis RudaitisMantas MinkauskasDaniel NaumovasTumas BeinortasLaimonas Grikeviius. (2024). Immunogenicity and clinical effectiveness of mrna vaccine booster against sars‐cov‐2 omicron in patients with haematological malignancies: a national prospective cohort study. British Journal of Haematology, 204(2), 497-506.

[6] Abid, M. B., Rubin, M., Ledeboer, N., Szabo, A. , Longo, W. , & Mohan, M. , et al. (2022). Efficacy of a third sars-cov-2 mrna vaccine dose among hematopoietic cell transplantation, car tcell, and bite recipients. Cancer Cell, 40(4), 340-342.

[7] Oyama, R., Ishigame, H., & Tanaka, HirokiTateshita, NahoItazawa, MoekoImai, RyosukeNishiumi, NaomasaKishikawa, Jun-ichiKato, TakayukiAnindita, JessicaNishikawa, YoshifumiMaeki, MasatoshiTokeshi, ManabuTange, KotaNakai, YutaSakurai, YuOkada, TakaharuAkita, Hidetaka. (2023). An ionizable lipid material with a vitamin e scaffold as an mrna vaccine platform for efficient cytotoxic t cell responses. ACS nano, 17(19), 18758-18774.

[8] Yang, X. , Jiang, S. , Liu, F. , Li, Z. , Liu, W. , & Zhang, X. , et al. (2024). Hcmv ie1/ie1mut therapeutic vaccine induces tumor regression via intratumoral tertiary lymphoid structure formation and peripheral immunity activation in glioblastoma multiforme. Molecular Neurobiology, 61(8), 5935-5949.

[9] Hee, C. , Kollenda, S. , Rotan, O. , Pastille, E. , & Knuschke, T. (2019). A tumor-peptide-based nanoparticle vaccine elicits efficient tumor growth control in antitumor immunotherapy. Molecular Cancer Therapeutics, 18(6), 1069-1080.

[10] Luo, Y. , Lin, C. , Zou, Y. , Ju, F. , Ren, W. , & Lin, Y. , et al. (2020). Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. Oncoimmunology, 9(1), 1726168.

[11] Wang, Q. T. , Nie, Y. , Sun, S. N. , Lin, T. , Han, R. J. , & Jiang, J. , et al. (2020). Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunology, Immunotherapy, 69(7), 1375-1387.

[12] Ye, X. , Liang, X. , Chen, Q. , Miao, Q. , Chen, X. , & Zhang, X. , et al. (2019). Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy. ACS nano, 13(3), 2956-2968.

[13] A, E. J. M. H., A, J. R. V. B., Chung T. Lê a, A, S. L., B, N. S., & C, K. H. M., et al. (2019). Corrigendum to "an improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature" [vaccine 36(21) 3054–3060]. Vaccine, 37(30), 4231-4232.

[14] Wu, X., Yin, Z, Mckay, C. , Pett, C. , Yu, J. , & Schorlemer, M. , et al. (2018). Protective epitope discovery and design of muc1-based vaccine for effective tumor protections in immunotolerant mice. Journal of the American Chemical Society, 140(48), 16596-16609.

[15] Nakata, J., Nakajima, H., Hayashibara, H. , Imafuku, K. , & Sugiyama, H. (2018). Extremely strong infiltration of wt1-specific ctls into mouse tumor by the combination vaccine with wt1-specific ctl and helper peptides. Oncotarget, 9(89), 36029-36038.

[16] Tondini, E., Arakelian, T., Oosterhuis, K., Camps, M., & Ossendorp, F. (2019). A poly-neoantigen dna vaccine synergizes with pd-1 blockade to induce t cell-mediated tumor control. OncoImmunology, 8(11), 1652539.

[17] Guo, M., Luo, B., Pan, M. , Li, M. , & Dou, J. (2020). Muc1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine. International Immunopharmacology, 85(16), 106631.

[18] Osborne, N., Sundseth, R. , Burks, J. , Cao, H. , & Smith, J. P. (2019). Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunology, Immunotherapy, 68(10), 1635-1648.

[19] Wang, Y. , Liu, J. , Ma, X. , & Liang, X. J. (2018). Nanomaterial-assisted sensitization of oncotherapy. Nano Research, 11(006), 2932-2950.

[20] Huang, L., Yang, C., & Chen, Z. X. H. (2023). Crispr-mediated base editing: promises and challenges for a viable oncotherapy strategy. Human gene therapy, 34(15/16), 669-681.

[21] Hu, Y. , Bai, S. , Fan, X. , Zhou, F. , Chen, B. , & Tan, S. , et al. (2022). Autocatalytic oncotherapy nanosystem with glucose depletion for the cascade amplification of hypoxia-activated chemotherapy and h. Biomaterials science, 10(9), 2358-2369.

[22] Zhan, J. Y. , Liu, R. , & Zhang, J. J. (2021). Progress of stimuli-responsive nanomaterials in tumor analysis. Chinese Journal of Analytical Chemistry, 49(7), 1133-1141.